温抗体型自身免疫性溶血性贫血的治疗策略
温抗体型自身免疫性溶血性贫血由IgG自身抗体介导红细胞破坏,骨髓代偿能力决定临床严重程度。治疗包括糖皮质激素、脾切除、免疫抑制剂和利妥昔单抗,后者越来越多用于激素难治性病例。本文通过5例病例探讨诊断、激素使用、二线治疗选择及难治/复发患者的再评估等关键问题。
要点
- 温抗体型AIHA的临床异质性大,需根据发病机制和骨髓代偿能力评估病情。
- 利妥昔单抗在激素难治性病例中应用日益增多,但二线选择需权衡利妥昔单抗与脾切除。
- 复发/难治病例需定期再评估,警惕演变为MDS或骨髓衰竭综合征。
核心结论
- 温抗体型AIHA由IgG自身抗体介导红细胞破坏,可伴或不伴补体激活,临床异质性和病程不可预测。
- 利妥昔单抗在激素难治性病例中的应用日益增多,基于文献和少数前瞻性试验证据。
研究设计与样本
- 本文为综述,通过5例患者病例研究探讨温抗体型AIHA的诊断和治疗关键问题。
主要发现
- 抗体依赖的细胞介导细胞毒作用由巨噬细胞/活化淋巴细胞在淋巴器官和脾脏执行(血管外溶血)。
- 骨髓代偿能力决定临床严重程度,不同致病机制及其复杂相互作用和随时间变化可解释疾病异质性。
- 疾病可为原发性、药物诱导或与淋巴增殖性肿瘤、自身免疫病、感染、免疫缺陷、实体瘤或移植相关。
临床怎么用
- 诊断需明确并正确使用激素治疗。
- 二线治疗需在利妥昔单抗和脾切除之间权衡选择。
- 复发/难治病例需定期再评估,以评估是否演变为骨髓增生异常综合征或骨髓衰竭综合征。
- 严重/急性疾病且高复发风险者管理困难,需特别关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by immunoglobulin G (IgG) autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages/activated lymphocytes occurs in the lymphoid organs and spleen (extravascular hemolysis). The ability of the bone marrow (BM) to compensate determines clinical severity. The different pathogenic mechanisms, their complex interplay, and changes over time may explain wAIHA's great clinical heterogeneity and unpredictable course. The disease may be primary, drug induced, or associated with lymphoproliferative neoplasms, autoimmune and infectious diseases, immunodeficiencies, solid tumors, or transplants. Therapeutic interventions include steroids, splenectomy, immunosuppressants, and rituximab; the latter is increasingly used in steroid-refractory cases based on evidence from the literature and a few prospective trials. We present 5 patient case studies highlighting important issues: (1) the diagnosis and proper use of steroid therapy, (2) the concerns about the choice between rituximab and splenectomy in second-line treatment, (3) the need of periodical re-evaluation of the disease to assess the possible evolution of relapsed/refractory cases in myelodysplastic and BM failure syndromes, and (4) the difficulties in managing cases of severe/acute disease that are at high risk of relapse. Incorporating novel targeted therapies into clinical practice will be an exciting challenge in the future.
引用
- Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. Blood. 2021. PMID: 33512406. doi:10.1182/blood.2019003808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。